Trends and factors affecting in-hospital mortality of patients with pulmonary arterial hypertension
DOI:
https://doi.org/10.18203/2320-6012.ijrms20242617Keywords:
Endothelin receptor, Heart failure, Pulmonary arterial hypertension, Pulmonary hypertension, Pulmonary vascular diseaseAbstract
Background: Pulmonary arterial hypertension (PAH) can be fatal without prompt treatment, but targeted therapies have greatly improved life expectancy in the 21st century. Despite these advances, PAH still involves high morbidity and mortality. Over the past decade, new drugs have been approved for PAH, yet research remains limited, and optimal management guidelines are lacking.
Methods: This retrospective study used the NIS database from 2016 to 2020 to examine PAH patients. Univariate and multivariate analyses were conducted, adjusting for confounders and Elixhauser comorbidity index was used to assess baseline comorbidity impact. Primary outcomes included mortality trends and factors influencing mortality. Secondary outcomes focused on length of stay and hospitalization charges.
Results: PAH admissions increased from 3.8% in 2016 to 30.36% in 2020s. A mortality rate of 6.4% was observed. Despite advancements in therapies, no significant difference in mortality rates was observed during these years. However, total hospitalization charges increased from 2016 to 2020. Age and race significantly influenced mortality. Female gender was associated with lower mortality, while the northeastern and western US had the highest mortality rates compared to the Midwest and South. Uninsured status was linked to higher mortality odds, while obesity had a protective effect. No significant difference in length of stay was noted.
Conclusions: This study summarized PAH trends and outcomes from 2016 to 2020, identifying predictive factors for inpatient mortality, length of hospital stays, and treatment costs.
References
Ruopp NF, Cockrill BA. Diagnosis and treatment of pulmonary arterial hypertension: a review. JAMA. 2022;327(14):1379-91.
Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2019 J;53(1).
Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25S):D34-41.
Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, et al. A global view of pulmonary hypertension. Lancet Respir Med. 2016;4(4):306-22.
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1):2200879.
Kim D, George MP. Pulmonary hypertension. Med Clin North Am. 2019;103(3):413-23.
Levine DJ. Pulmonary arterial hypertension: updates in epidemiology and evaluation of patients. Am J Managed Care. 2021;27(3 Suppl):S35-41.
Jacobs W, van de Veerdonk MC, Trip P, de Man F, Heymans MW, Marcus JT, et al. The right ventricle explains sex differences in survival in idiopathic pulmonary arterial hypertension. Chest. 2014;145(6):1230-6.
McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial hypertension. J Am Coll Cardiol. 2015;65(18):1976-97.
Patan S. Vasculogenesis and angiogenesis as mechanisms of vascular network formation, growth and remodeling. Journal of neuro-oncology, 2020;50(1-2):1-15.
Bourgeois A, Omura J, Habbout K, Bonnet S, Boucherat O. Pulmonary arterial hypertension: new pathophysiological insights and emerging therapeutic targets. Int J Biochem Cell Biol. 2018;104:9-13.
Ranchoux B, Harvey LD, Ayon RJ, Babicheva A, Bonnet S, Chan SY, et al. Endothelial dysfunction in pulmonary arterial hypertension: an evolving landscape (2017 Grover Conference Series). Pulmon Circ. 2018;8(1):2045893217752912.
Prins KW, Thenappan T. World Health Organization group I pulmonary hypertension: epidemiology and pathophysiology. Cardiol Clin. 2016;34(3):363-74.
Boucherat O, Vitry G, Trinh I, Paulin R, Provencher S, Bonnet S. The cancer theory of pulmonary arterial hypertension. Pulmon Circ. 2017;7(2):285-99.
Evans JD, Girerd B, Montani D, Wang XJ, Galiè N, Austin ED, et al. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respir Med. 2016;4(2):129-37.
David L, Mallet C, Mazerbourg S, Feige JJ, Bailly S. Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood, 2007;109(5):1953-61.
Upton PD, Davies RJ, Trembath RC, Morrell NW. Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells. J Biol Chem. 2009;284(23):15794-804.
Drake KM, Zygmunt D, Mavrakis L, Harbor P, Wang L, Comhair SA, et al. Altered MicroRNA processing in heritable pulmonary arterial hypertension: an important role for Smad-8. Am J Respir Crit Care Med. 2011;184(12):1400-8.
Wertz JW, Bauer PM. Caveolin-1 regulates BMPRII localization and signalling in vascular smooth muscle cells. Biochem Biophys Res Commun. 2008;375(4):557-61.
Austin ED, Cogan JD, West JD, Hedges LK, Hamid R, Dawson EP, et al. Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir J. 2009;34(5):1093-9.
Frost A, Badesch D, Gibbs JS, Gopalan D, Khanna D, Manes A, et al. Diagnosis of pulmonary hypertension. Eur Respir J. 2019;53(1).
Hammerstingl C, Schueler R, Bors L, Momcilovic D, Pabst S, Nickenig G, et al. Diagnostic value of echocardiography in the diagnosis of pulmonary hypertension. PloS One. 2012;7(6):e38519.
Fisher MR, Forfia PR, Chamera E, Housten-Harris T, Champion HC, Girgis RE, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179(7):615-21.
Channick R, Preston I, Klinger JR. Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors. Clin Chest Med. 2013;34(4):811-24.
Auth R, Klinger JR. Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension. Exp Opin Investig Drugs. 2023;32(11):1025-42.
Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834-44.
Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376-87.
Davis KK, Lilienfeld DE, Doyle RL. Increased mortality in African Americans with idiopathic pulmonary arterial hypertension. J Nat Med Assoc. 2008;100(1):69-72.
